N-alpha-苄氧羰基-L-赖氨酸对硝基苯基酯 | 4272-71-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-alpha-苄氧羰基-L-赖氨酸对硝基苯基酯
• 中文别名: N-α-苄氧羰酰基-L-赖氨酸对硝基苯酯盐酸盐
• 英文名称: N^α-benzyloxycarbonyl-L-lysine p-nitrophenyl ester
• 英文别名: α-carbobenzoxy-L-lysine p-nitrophenyl ester；N-carbobenzoxy-L-lysine p-nitrophenyl ester；N-α-CBz-L-lysine-4-nitrophenylester；Z-L-Lys-PNP；Z-Lys-pNP；α-N-Benzyloxycarbonyl-L-lysin-p-nitrophenylester；p-Nitrophenyl N2-(benzyloxycarbonyl)-L-lysinate；(4-nitrophenyl) (2S)-6-amino-2-(phenylmethoxycarbonylamino)hexanoate
• CAS: 4272-71-3
• 化学式: C₂₀H₂₃N₃O₆
• 分子量: 401.419
• InChiKey: VMKGUOYDQYWEJP-SFHVURJKSA-N

物化性质

• 熔点：
  150-152°C
• 沸点：
  606.3±55.0 °C(Predicted)
• 密度：
  1.274±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  29
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  137
• 氢给体数：
  2
• 氢受体数：
  7

安全信息

• 海关编码：
  2924299090

SDS

Name:	N-alpha-Carbobenzyloxy-L-lysine 4-nitrophenyl ester hydrochloride Material Safety Data Sheet
Synonym:	N-alpha-CBZ-L-lysine 4-nitrophenylester hydrochlorid
CAS:	4272-71-3

Section 1 - Chemical Product MSDS Name:N-alpha-Carbobenzyloxy-L-lysine 4-nitrophenyl ester hydrochloride Material Safety Data Sheet
Synonym:N-alpha-CBZ-L-lysine 4-nitrophenylester hydrochlorid

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
4272-71-3	N-alpha-Carbobenzyloxy-L-lysine 4-nitr	100	224-265-9

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Never give anything by mouth to an unconscious person. Get medical aid immediately.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Keep refrigerated. (Store below 4C/39F.)

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 4272-71-3: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 150.00 - 152.00 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C20H23N3O6.HCl
Molecular Weight: 437.88

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stability unknown.
Conditions to Avoid:
Incompatible materials, dust generation, strong oxidants.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Irritating and toxic fumes and gases.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 4272-71-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
N-alpha-Carbobenzyloxy-L-lysine 4-nitrophenyl ester hydrochloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 4272-71-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 4272-71-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 4272-71-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-alpha-苄氧羰基-L-赖氨酸对硝基苯基酯 在 palladium on activated charcoal 吡啶 、 sodium hydroxide 、 氢气 、 N,N'-二环己基碳二亚胺 作用下， 以 1,4-二氧六环 、 乙醇 、 氯仿 、 水 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 19.5h， 生成 吲哚-3-乙酰基-epsilon-赖氨酸
  参考文献：
  名称：

  N-ε-(吲哚-3-乙酰基)-l-赖氨酸的合成

  摘要：

  摘要 Ne-(indole-3-acetyl)-l-Lysine (e-IAA-Lys) 及其 N-α-乙酰衍生物 (Ac-e-IAA-Lys)，吲哚-3-乙酸代谢产物(IAA) 在丁香假单胞菌亚种中。savastanoi 是通过将 IAA 与 N-α-CBz-l-赖氨酸对硝基苯酯结合而合成的。使用相同的合成策略获得非天然缀合物 N-α-(吲哚-3-乙酰基)-l-赖氨酸 (α-IAA-Lys) 及其 Ne-乙酰基衍生物 (Ac-α-IAA-Lys)。对小麦胚芽鞘生长素活性的比较生物测定证明，e-IAA-Lys 和 Ac-e-IAA-Lys 显着刺激了它们的生长，尽管它们的活性远低于 IAA。α-IAA-Lys 和 Ac-α-IAA-Lys 未显示活性。

  DOI：

  10.1016/0031-9422(93)85388-8
• 作为产物：
  描述：

  N6-[叔丁氧羰基]-N2-[苄氧羰基]-L-赖氨酸 4-硝基苯基酯 在 盐酸 作用下， 生成 N-alpha-苄氧羰基-L-赖氨酸对硝基苯基酯
  参考文献：
  名称：

  水解酶溶液浓度的确定：α-胰凝乳蛋白酶，胰蛋白酶，木瓜蛋白酶，弹性蛋白酶，枯草杆菌蛋白酶和乙酰胆碱酯酶。

  摘要：

  DOI：

  10.1021/ja00976a034

文献信息

• DIPEPTIDE MIMETICS OF NGF AND BDNF NEUROTROPHINS
  申请人：Seredenin Sergey Borisovich

  公开号：US20110312895A1

  公开（公告）日：2011-12-22

  The invention relates to compounds having either agonist or antagonist activities for the neurotrophins NGF and BDNF and represented by monomeric or dimeric substituted dipeptides that are analogs of the exposed portions of loop 1 or loop 4 regions of these neurotrophins near or at a beta-turn of the respective loop. N-acylated substituents of these dipeptides are biostereoisomers of the amino acid residues preceding these dipeptide sequences in the neurotrophin primary structure. The dimeric structure is produced advantageously by using hexamethylenediamine to which dipeptides are attached via their carboxyl groups. The claimed compounds displayed neuroprotective and differentiation-inducing activities in cellular models and enhanced the amount of phosphorylated tyrosine kinase A and the heat shock proteins Hsp32 and Hsp70 in the concentration range of 10 −9 to 10 −5 M. They also displayed neuroprotective, anti-parkinsonian, anti-stroke, anti-ischemic, anti-depressant and anti-amnestic activities in animal models and were active in experimental models of Alzheimer's disease. These in vivo effects of the claimed compounds are displayed in the dose range of 0.01 to 10 mg/kg when administered intraperitoneally.

  该发明涉及具有神经营养因子NGF和BDNF的激动剂或拮抗剂活性的化合物，这些化合物由单体或二聚体取代二肽代表，这些二肽代表这些神经营养因子的环1或环4区域的暴露部分的类似物，靠近或在各自环的β-转弯处。这些二肽的N-酰化取代物是神经营养因子原始结构中这些二肽序列之前的氨基酸残基的生物立体异构体。通过使用己二胺，优点地产生二聚体结构，二肽通过它们的羧基团连接到己二胺上。所述化合物在细胞模型中显示出神经保护和诱导分化活性，并在浓度范围为10^(-9)到10^(-5)M时增加了磷酸化酪氨酸激酶A和热休克蛋白Hsp32和Hsp70的量。它们还在动物模型中显示出神经保护、抗帕金森病、抗中风、抗缺血、抗抑郁和抗遗忘活性，并在阿尔茨海默病的实验模型中活跃。所述化合物的这些体内效应在腹腔内给药时的剂量范围为0.01至10毫克/千克。
• Proteinase inhibitor
  申请人：SUNTORY LIMITED

  公开号：EP0393457A1

  公开（公告）日：1990-10-24

  A proteinase inhibitory compound represented by the following general formula (1): wherein R₁ represents a straight-chain or branched acyl group having 2 to 10 carbon atoms, a branched-, cyclic- or polycyclic-alkyloxycarbonyl group having 4 to 15 carbon atoms, a substituted- or unsubstituted-benzyloxycarbonyl group, a 2,2,2-trichloroethyloxycarbonyl group, a 2-­(trimethylsilyl)ethyloxycarbonyl group, a p-toluenesulfonyl group, an o-nitrophenylsulfenyl group, a diphenylphosphono­thioyl group, a triphenylmethyl group or a 2-benzoly-1-­methylvinyl group; R₂ represents a hydrogen atom; or R₁ and R₂ may together form a phthaloyl group; R₃ represents an isobutyl group, a n-butyl group or an isopropyl group and the above-mentioned R₁ can be an unsubstituted-benzyloxycarbonyl group provided that R₃ is a n-butyl group; and R₄ represents a n-butyl group.

  由以下通式(1)代表的蛋白酶抑制剂化合物： 其中 R₁ 代表具有 2 至 10 个碳原子的直链或支链酰基，具有 4 至 15 个碳原子的支链、环或多环烷氧基羰基，取代或未取代的苄氧基羰基，2、2，2-三氯乙基氧羰基、2-（三甲基硅基）乙基氧羰基、对甲苯磺酸基、邻硝基苯磺酰基、二苯基膦酰基、三苯基甲基或 2-苯甲酰基-1-甲基乙烯基； R₂ 代表氢原子；或 R₁ 和 R₂ 可共同形成邻苯二甲酰基； R₃ 代表异丁基、正丁基或异丙基，上述 R₁ 可以是未取代的苄氧羰基，条件是 R₃ 是正丁基；以及 R₄ 代表一个正丁基。
• Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies
  申请人：——

  公开号：US20020090695A1

  公开（公告）日：2002-07-11

  The present invention relates to novel human KTPI polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human KTPI polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human KTPI polypeptides.

  本发明涉及新型人 KTPI 多肽和含有编码这种多肽的基因编码区的分离核酸。本发明还提供了生产人 KTPI 多肽的载体、宿主细胞、抗体和重组方法。本发明还涉及诊断和治疗与这些新型人类 KTPI 多肽有关的疾病的方法。
• Nucleic acids, proteins, and antibodies
  申请人：——

  公开号：US20030044890A1

  公开（公告）日：2003-03-06

  The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

  本发明涉及新型蛋白质。更具体地说，本发明提供了编码新型多肽的分离核酸分子。本发明提供了新型多肽和与这些多肽结合的抗体。本发明还提供了生产人类多核苷酸和/或多肽以及抗体的载体、宿主细胞、重组和合成方法。本发明还涉及用于诊断、治疗、预防和/或预后与这些新型多肽有关的疾病的诊断和治疗方法。本发明进一步涉及鉴定本发明多核苷酸和多肽的激动剂和拮抗剂的筛选方法。本发明进一步涉及抑制或增强本发明多肽的产生和功能的方法和/或组合物。
• Digestive/laxative compositions
  申请人：——

  公开号：US20040058025A1

  公开（公告）日：2004-03-25

  The use of actinidin as a digestive/laxative aid. Method of obtaining actinidin from fruit.

  将放线菌素用作助消化/通便剂。从水果中获取放线菌素的方法。